TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21351291

Group type: EXPERIMENTAL
Intervention: Multiple treatments including Chinese herbs, acupuncture, and massage therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propensity score regression adjustment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propensity score weighting
Number of subjects: 0
Study: 20212271

Group type: EXPERIMENTAL
Intervention: Perindopril-based blood pressure-lowering therapy
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 17564952

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 15735660

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) from a sibling donor in second complete remission
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: FLT3 internal tandem duplication (ITD) assessment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Donor availability
Number of subjects: 92
Study: 12233895

Group type: EXPERIMENTAL
Intervention: Eradication therapy (omeprazole 20 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 7 days)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Omeprazole alone (20 mg once daily)
Number of subjects: 919

Group type: COMPARATOR
Intervention: H. pylori negative patients (omeprazole 20 mg once daily)
Number of subjects: 919
Study: 10081035

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily for 2 weeks)
Number of subjects: 13
Study: 7752627

Group type: EXPERIMENTAL
Intervention: Alcohol session (0.625 g/kg body weight of 80-proof ethyl alcohol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo session
Number of subjects: 10
Study: 2268634

Group type: EXPERIMENTAL
Intervention: Topical application of fluoride varnish (Duraphat) on cavity walls
Number of subjects: 191

Group type: COMPARATOR
Intervention: Untreated restorations
Number of subjects: 191
Study: 6780021

Group type: EXPERIMENTAL
Intervention: Real bilateral electric convulsion therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Simulated bilateral electric convulsion therapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Real bilateral electric convulsion therapy after switching from simulated treatment
Number of subjects: 22
Study: 31815655

Group type: EXPERIMENTAL
Intervention: Chinese pediatric Tuina (15-25 min treatment once per day for 3 consecutive days)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sham pediatric Tuina (15-25 min treatment once per day for 3 consecutive days)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Chinese pediatric Tuina
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sham pediatric Tuina
Number of subjects: 122
Study: 28209636

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet (target <2 g sodium per day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 58
Study: 26513032

Group type: EXPERIMENTAL
Intervention: Healthy Babies Healthy Moms (HBHM)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Baby Basics (BB)
Number of subjects: 83
Study: 23863676

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy
Number of subjects: 152
Study: 22691430

Group type: EXPERIMENTAL
Intervention: DTaP₅-IPV-Hib vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTaP₃-HBV-IPV/Hib
Number of subjects: 0
Study: 19556533

Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment (specifics not provided)
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Patients fulfilling trial enrollment criteria
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Patients not fulfilling trial enrollment criteria
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Trial-eligible patients
Number of subjects: 972
Study: 16999250

Group type: EXPERIMENTAL
Intervention: LACE (Listening and Communication Enhancement) program, received immediately after baseline testing.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group, received no intervention for one month before crossover to LACE.
Number of subjects: 65
Study: 15632895

Group type: EXPERIMENTAL
Intervention: Glucose-Insulin-Potassium (GIK) intravenous infusion for 24 hours
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Reviparin) injection twice daily for 7 days
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Placebo injection twice daily for 7 days
Number of subjects: 20000
Study: 11684928

Group type: EXPERIMENTAL
Intervention: HIV+LD
Number of subjects: 6
Study: 9299912

Group type: EXPERIMENTAL
Intervention: Indirect task with short lag (repeated after a single intervening trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect task with long lag (repeated after a mean of 10 trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct task with short lag (repeated after a single intervening trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct task with long lag (repeated after a mean of 10 trials)
Number of subjects: 0
Study: 7524736

Group type: EXPERIMENTAL
Intervention: nIFN alpha (3 MU) intramuscularly three times weekly
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: nIFN alpha (3 MU) intramuscularly three times weekly plus 6-methyl-prednisolone (16 mg/d orally on non-IFN days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 6-methyl-prednisolone (16 mg/d orally) only
Number of subjects: 65

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: nIFN alpha plus PDN
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: nIFN alpha alone
Number of subjects: 65

Group type: COMPARATOR
Intervention: PDN alone
Number of subjects: 65
Study: 3278969

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31501081

Group type: EXPERIMENTAL
Intervention: Audio-only
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Audio-video
Number of subjects: 125

Group type: COMPARATOR
Intervention: Visual-only
Number of subjects: 125
Study: 29764380

Group type: EXPERIMENTAL
Intervention: Osteoporosis
Number of subjects: 1467

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1467

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1467
Study: 26831832

Group type: EXPERIMENTAL
Intervention: Social Support Seeking (SSS)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Self-Efficacy Building (SEB)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Comparison between SSS and SEB
Number of subjects: 165
Study: 26044576

Group type: EXPERIMENTAL
Intervention: High traction force MCD (51-100 N)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Medium traction force MCD (21-50 N)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low traction force MCD (0-20 N)
Number of subjects: 48
Study: 23582353

Group type: EXPERIMENTAL
Intervention: AREDS formulation (high-dose antioxidants C, E, β-carotene, and zinc)
Number of subjects: 4757

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4757

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 4757
Study: 20570559

Group type: EXPERIMENTAL
Intervention: Vandetanib plus docetaxel
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Vandetanib plus docetaxel (in women)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Placebo plus docetaxel (in women)
Number of subjects: 1391
Study: 18180976

Group type: EXPERIMENTAL
Intervention: 100 mg monthly oral ibandronate
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: 150 mg monthly oral ibandronate
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Both doses of ibandronate
Number of subjects: 719
Study: 16421061

Group type: EXPERIMENTAL
Intervention: Aquatic programme (experimental group, n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 18
Study: 14624185

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sertraline and CBT
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo and CBT
Number of subjects: 82
Study: 10831555

Group type: EXPERIMENTAL
Intervention: ICSI with husband's spermatozoa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 0
Study: 10174220

Group type: EXPERIMENTAL
Intervention: Photographic information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of photographic and written information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written material alone
Number of subjects: 0
Study: 8155112

Group type: EXPERIMENTAL
Intervention: Direct visual intubation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Intubation aided by a gum elastic bougie
Number of subjects: 157
Study: 3034538

Group type: EXPERIMENTAL
Intervention: PDD 10 mg per day X 10, every 3 weeks (hepatic arterial perfusion)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 5‐Fu 250 mg per day X 4, every week and thio‐tepa (TSPA) 10 mg, twice a week (hepatic arterial perfusion)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: PDD 20 mg per day X 5, every 3 weeks (intravenous chemotherapy)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 5‐Fu 500 mg and TSPA 10 mg, twice a week (intravenous chemotherapy)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: All patients receiving hepatic arterial perfusion
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intravenous PDD
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intravenous control group
Number of subjects: 82
Study: 29280011

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 26667118

Group type: EXPERIMENTAL
Intervention: Minimally invasive approach based on atraumatic restorative treatment (ART) procedures
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard-care approach
Number of subjects: 254
Study: 22559255

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 474

Group type: COMPARATOR
Intervention: Duloxetine 60 mg
Number of subjects: 474
Study: 20415692

Group type: EXPERIMENTAL
Intervention: Insulin glargine (GLA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 28
Study: 18093252

Group type: EXPERIMENTAL
Intervention: Coracten (encapsulated mini-tablet)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: N-GITS (30-mg osmotic, constant-release nifedipine gastrointestinal therapeutic system)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison between Coracten and N-GITS
Number of subjects: 44
Study: 15978926

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 338

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 338
Study: 12201975

Group type: EXPERIMENTAL
Intervention: Delirium symptoms post-surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (non-delirious patients)
Number of subjects: 52
Study: 10475139

Group type: EXPERIMENTAL
Intervention: 3 mg oral budesonide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8757005

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan (6 mg)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Dihydroergotamine (DHE) nasal spray (1 mg plus optional 1 mg)
Number of subjects: 266
Study: 1761665

Group type: EXPERIMENTAL
Intervention: Superovulation alone
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Superovulation with IUI
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Superovulation with IPI
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Superovulation with GIFT
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Superovulation with IVF
Number of subjects: 444
Study: 7106687

Group type: EXPERIMENTAL
Intervention: Phlebodril (fixed combination)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trimethylhesperidinchalcone
Number of subjects: 20
Study: 31144432

Group type: EXPERIMENTAL
Intervention: Adherence to the Mediterranean dietary score
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: 30 s chair stand test
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Inadequate vitamin C consumption
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Visceral fat
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Leucocyte count
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Neutrophils and monocytes
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 1535
Study: 30016177

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcineurin inhibitors
Number of subjects: 120
Study: 26858430

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (12-h inverted behavioral and environmental cycles for three days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 0
Study: 24982780

Group type: EXPERIMENTAL
Intervention: Trospium 60 mg/day and Solifenacin 20 mg/day during two cycles (1.5 and 1 month with one month interval)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Trospium 60 mg/day and Solifenacin 20 mg/day during one cycle therapy
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo during second cycle
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control groups (A3, B3)
Number of subjects: 313
Study: 22367125

Group type: EXPERIMENTAL
Intervention: Pellet stove condition
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 16
Study: 19920098

Group type: EXPERIMENTAL
Intervention: Adenovirus/prostate-specific antigen (PSA) vaccine
Number of subjects: 32
Study: 17214953

Group type: EXPERIMENTAL
Intervention: Concurrent verbal protocol method
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Retrospective verbal protocol method
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Quantitative analysis of concurrent reports
Number of subjects: 18
Study: 15201372

Group type: EXPERIMENTAL
Intervention: Tongue acupuncture (TAC), n = 22
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (sham acupuncture), n = 11
Number of subjects: 33
Study: 11695210

Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 83

Group type: COMPARATOR
Intervention: Colgate Total Toothpaste
Number of subjects: 83
Study: 9794929

Group type: EXPERIMENTAL
Intervention: Consensus Interferon (CIFN) 9 microgram for 6 months
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Retreatment with Consensus Interferon (CIFN) 15 microgram
Number of subjects: 232
Study: 7658483

Group type: EXPERIMENTAL
Intervention: 1.0 g calcium
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 2.0 g calcium
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Combined calcium groups
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 2520621

Group type: COMPARATOR
Intervention: 150 mg ranitidine b.d.
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine q.d.s.
Number of subjects: 138
Study: 843418

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study: 30429592

Group type: EXPERIMENTAL
Intervention: 4 session home‐based CBT (minimal contact (MC‐CBT))
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: 10 session clinic‐based CBT (standard (S‐CBT))
Number of subjects: 436

Group type: COMPARATOR
Intervention: 4 session IBS education (EDU)
Number of subjects: 436
Study: 27815631

Group type: EXPERIMENTAL
Intervention: Suction-tube-assisted endoscopic septoplasty (Group 2)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Traditional septoplasty (Group 1)
Number of subjects: 434
Study: 26416025

Group type: EXPERIMENTAL
Intervention: Internet-based exercise training (IBET)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Standard physical therapy (PT)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Wait list (WL) control group
Number of subjects: 350
Study: 23560480

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercise (VRE) program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (CG) - diabetes education only
Number of subjects: 55
Study: 21864622

Group type: EXPERIMENTAL
Intervention: 7.5-mcg or 30-mcg of hemagglutinin intramuscularly
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 121
Study: 19644190

Group type: EXPERIMENTAL
Intervention: Lercamen (lercadipine) 10-20 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 80
Study: 17905575

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg two inhalations twice daily and as needed
Number of subjects: 2309

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/500 microg one inhalation twice daily plus terbutaline as needed
Number of subjects: 2309
Study: 15388510

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg at week 0, 2, and 6)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12196773

Group type: EXPERIMENTAL
Intervention: Nasobiliary catheter (NBC group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Indwelling stent (stent group)
Number of subjects: 79
Study: 9787699

Group type: EXPERIMENTAL
Intervention: High iron weaning diet (8.2 +/‐ 2.9 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group weaning diet (5.2 +/‐ 3.4 mg/day)
Number of subjects: 62
Study: 8925517

Group type: EXPERIMENTAL
Intervention: Weekly wine consumption
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Occasional consumption of spirits
Number of subjects: 177

Group type: COMPARATOR
Intervention: Abstaining from alcohol
Number of subjects: 177

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 177

Group type: COMPARATOR
Intervention: Beer consumption
Number of subjects: 177
Study: 2673511

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (15 mg) followed by oral metoprolol (200 mg daily for 15 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 31096478

Group type: EXPERIMENTAL
Intervention: Balloon-stent kissing technique (BSKT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Jailed wire technique (JWT)
Number of subjects: 89
Study: 28558732

Group type: EXPERIMENTAL
Intervention: B. infantis supplementation (BiLS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lactation support alone (LS)
Number of subjects: 80
Study: 25417843

Group type: EXPERIMENTAL
Intervention: Trivia Game (treatment group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 23325671

Group type: EXPERIMENTAL
Intervention: Real-time elastography-guided biopsy
Number of subjects: 231

Group type: COMPARATOR
Intervention: Grey-scale ultrasound-guided biopsy
Number of subjects: 231
Study: 22047559

Group type: EXPERIMENTAL
Intervention: Anti-inhibitor coagulant complex (AICC) prophylaxis at a target dose of 85 U/kg (±15%) on 3 nonconsecutive days per week
Number of subjects: 34

Group type: COMPARATOR
Intervention: On-demand therapy (AICC at a target dose of 85 U/kg [±15%] used for bleeding episodes)
Number of subjects: 34
Study: 19925045

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 25620

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 25620

Group type: COMPARATOR
Intervention: Combination of Ramipril and Telmisartan
Number of subjects: 25620
Study: 19780298

Group type: EXPERIMENTAL
Intervention: Primary cisplatin-based intraperitoneal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cisplatin-based treatment
Number of subjects: 0
Study: 10400014

Group type: EXPERIMENTAL
Intervention: Acetylsalicylate (1 g IV) after bradykinin infusion into the iliac artery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acetylsalicylate (1 g IV) after bradykinin infusion into the left coronary artery
Number of subjects: 18
Study: 8531622

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diet only (D)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diet + cycling (DC)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diet + resistance training (DR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diet + resistance training + cycling (DRC)
Number of subjects: 44
Study: 2100324

Group type: EXPERIMENTAL
Intervention: Ranitidine, 50 mg i.v.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ranitidine, 50 mg i.v. and metoclopramide, 10 mg i.v.
Number of subjects: 48

Group type: COMPARATOR
Intervention: No medication (Control group)
Number of subjects: 48
Study: 7369098

Group type: EXPERIMENTAL
Intervention: Prajmalium bitartrate (60 mg orally, 20 mg every 4 hours)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lidocaine (2.1 mg/minute infusion, daily dose of 3 g)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no antiarrhythmic drug)
Number of subjects: 35
Study: 30675865

Group type: EXPERIMENTAL
Intervention: Maternal voice stimulation (listened to mothers' voice from 1 minute before heel blood collection to the end of the procedure)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine method of heel blood collection (control group)
Number of subjects: 72
Study: 28202358

Group type: EXPERIMENTAL
Intervention: Lipotoxin (onabotulinumtoxinA 200 U with 80 mg sphingomyelin)
Number of subjects: 90

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA in normal saline (200 U)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline alone
Number of subjects: 90
Study: 26164310

Group type: EXPERIMENTAL
Intervention: Blink blink animation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo version
Number of subjects: 34